NewAmsterdam, Menarini Cholesterol Drugs Receive Positive Opinion From CHMP
NewAmsterdam Pharma (NAMS) and Menarini said the EMA CHMP issued a positive opinion for Ubeslo (obicetrapib 10 mg) and Evlarco (obicetrapib 10 mg plus ezetimibe 10 mg) for adults with primary hypercholesterolemia. CHMP based on Phase 3 BROADWAY, BROOKLYN and TANDEM; LDL-C fell up to 40% with monotherapy and about 50% with the combo vs placebo. European Commission decision expected H2 2026.
How this was made
The 30-second read
Why it matters
This is a regulatory de-risking step for NewAmsterdam’s obicetrapib program in Europe, with a stated LDL-C efficacy and tolerability profile versus placebo, and a clear next milestone: the European Commission’s final decision in H2 2026.
Market read
Traders may adjust approval-probability and timeline assumptions for obicetrapib in Europe ahead of the European Commission’s final decision window.
What to watch
The article does not quantify probability of EC approval, competitive landscape, or any remaining regulatory questions; royalty and milestone economics depend on eventual net sales and timing.
Background
NewAmsterdam and Menarini announced a positive CHMP opinion for two obicetrapib-based cholesterol-lowering products in adults with primary hypercholesterolemia.
Ticker impact
NewAmsterdam received a positive CHMP opinion for obicetrapib (Ubeslo) and obicetrapib plus ezetimibe (Evlarco), with EC decision expected H2 2026.
Likely modest positive bias, with follow-through dependent on the European Commission’s final decision in H2 2026.
The article is a concrete regulatory milestone (CHMP positive opinion) tied to specific products and trial data, but it is not the final EC approval and the timeline is months away.
Market effects
Adds incremental validation for cholesterol-lowering pipeline candidates in Europe, potentially improving sentiment for competing lipid-lowering drug developers.
EU regulatory pathway progress can shift expectations for future cardiovascular/lipid drug approvals across member states.
Supports broader global confidence in obicetrapib’s clinical package, though the decision cited is EU-specific.
Counterpoint
A CHMP positive opinion is not the final European Commission decision, so the market may already price much of the upside and could fade the news if approval timing or labeling expectations change.
Key entities
- companyNewAmsterdam Pharma Company N.V.
Sponsor of obicetrapib clinical development; received the CHMP positive opinion for Ubeslo and Evlarco.
- companyMenarini Group
Holds exclusive commercialization rights for obicetrapib in Europe under a licensing agreement.
- regulatorEuropean Medicines Agency (EMA) CHMP
Committee that issued the positive opinion recommending marketing authorization.
- regulatorEuropean Commission
Expected to issue the final EU-wide marketing authorization decision in H2 2026.
